Dyne Therapeutics, Inc. (DYN)
NASDAQ: DYN · Real-Time Price · USD
14.70
+0.71 (5.08%)
At close: Jun 6, 2025, 4:00 PM
14.41
-0.29 (-1.97%)
After-hours: Jun 6, 2025, 4:32 PM EDT

Dyne Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2018 - 2019
Period Ending
Mar '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2018 - 2019
Selling, General & Admin
53.7962.4831.428.228.7213.45
Upgrade
Research & Development
343.31281.41210.76142.76121.3145.2
Upgrade
Operating Expenses
397.1343.89242.16170.96150.0358.65
Upgrade
Operating Income
-397.1-343.89-242.16-170.96-150.03-58.65
Upgrade
Interest Expense
------0.4
Upgrade
Interest & Investment Income
31.0226.927.642.920.740.06
Upgrade
Currency Exchange Gain (Loss)
-1.09-0.49-1.39-0.02--
Upgrade
Other Non Operating Income (Expenses)
0.01-----0.45
Upgrade
EBT Excluding Unusual Items
-367.17-317.45-235.91-168.07-149.28-59.44
Upgrade
Gain (Loss) on Sale of Investments
0.040.04-0.02-0.03-0.01-
Upgrade
Pretax Income
-367.13-317.42-235.94-168.1-149.29-59.44
Upgrade
Net Income
-367.13-317.42-235.94-168.1-149.29-59.44
Upgrade
Net Income to Common
-367.13-317.42-235.94-168.1-149.29-59.44
Upgrade
Shares Outstanding (Basic)
1019460525114
Upgrade
Shares Outstanding (Diluted)
1019460525114
Upgrade
Shares Change (YoY)
53.90%57.74%14.83%2.13%253.54%489.30%
Upgrade
EPS (Basic)
-3.62-3.37-3.95-3.23-2.93-4.13
Upgrade
EPS (Diluted)
-3.62-3.37-3.95-3.23-2.93-4.13
Upgrade
Free Cash Flow
-322.89-294.75-188.89-156.71-123.18-47.67
Upgrade
Free Cash Flow Per Share
-3.19-3.13-3.17-3.02-2.42-3.31
Upgrade
EBITDA
-395.31-342.21-240.49-169.28-148.94-57.95
Upgrade
D&A For EBITDA
1.791.671.671.681.090.7
Upgrade
EBIT
-397.1-343.89-242.16-170.96-150.03-58.65
Upgrade
Updated Feb 27, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q